Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Literature
1.
Kasatkar P, Ghosh K, Shetty S (2013) A common founder mutation p.P2063S in exon 36 of VWF in 11 unrelated Indian von Willebrand disease (VWD) families. Ann Hematol. doi:10.​1007/​s00277-013-1680-x
2.
Eikenboom J, Hilbert L, Ribba AS, Hommais A, Habart D, Messenger S, Al-Buhairan A, Guilliatt A, Lester W, Mazurier C, Meyer D, Fressinaud E, Budde U, Will K, Schneppenheim R, Obser T, Marggraf O, Eckert E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Goudemand J, Ingerslev J, Lethagen S, Hill F, Peake I, Goodeve A (2009) Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. J Thromb Haemost 7:1304–1312CrossRefPubMed
3.
Johansson AM, Halldén C, Säll T, Lethagen S (2011) Variation in the VWF gene in Swedish patients with type 1 von Willebrand disease. Ann Hum Genet 75:447–455CrossRefPubMed
4.
Wang QY, Song J, Gibbs RA, Boerwinkle E, Dong JF, Yu FL (2013) Characterizing polymorphisms and allelic diversity of von Willebrand factor gene in the 1000 Genomes. J Thromb Haemost 11:261–269PubMedCentralCrossRefPubMed
5.
Baronciani L, Cozzi G, Canciani MT, Peyvandi F, Srivastava A, Federici AB, Mannucci PM (2003) Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis 30:264–270CrossRefPubMed
6.
Gupta PK, Saxena R, Adamtziki E, Budde U, Oyen F, Obser T, Schneppenheim R (2008) Genetic defects in von Willebrand disease type 3 in Indian and Greek patients. Blood Cells Mol Dis 41:219–222CrossRefPubMed
7.
Ahmad F, Budde U, Jan R, Oyen F, Kannan M, Saxena R, Schneppenheim R (2013) Phenotypic and molecular characterisation of type 3 von Willebrand disease in a cohort of Indian patients. Thromb Haemost 109:652–660CrossRefPubMed
8.
Hampshire DJ, Abuzenadah AM, Cartwright A, Al-Shammari NS, Coyle RE, Eckert M, Al-Buhairan AM, Messenger SL, Budde U, Gürsel T, Ingerslev J, Peake IR, Goodeve AC (2013) Identification and characterisation of mutations associated with von Willebrand disease in a Turkish patient cohort. Thromb Haemost. doi:10.​1160/​TH13-02-0135
9.
Hampshire DJ, Goodeve AC (2011) The molecular basis of von Willebrand disease: the under investigated, the unexpected and the overlooked. Haematologica 96:798–800CrossRefPubMed
10.
Schneppenheim R, Budde U, Beutel K, Hassenpflug W-A, Hauch H, Obser T, Oyen F, Schneppenheim S, Schrum J (2009) Response to DDAVP in children with von Willebrand disease type 2. Hämostaseologie 29:143–148PubMed
Metadata
Title
p.P2063S: a neutral VWF variant masquerading as a mutation
Authors
Daniel J. Hampshire
Anne C. Goodeve
Publication date
01-03-2014
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 3/2014
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1817-y

Other articles of this Issue 3/2014

Annals of Hematology 3/2014 Go to the issue

Letter to the Editor

A diagnostic dilemma in AL(L)PS

Original Article

Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients

Letter to the Editor

PET-MRI hybrid imaging in a rare case of B cell lymphoblastic lymphoma with musculoskeletal manifestation

Original Article

Prevention, management and extent of adverse pregnancy outcomes in women with hereditary antithrombin deficiency

Original Article

Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma

Original Article

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits